Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1907-1916

  Moller P ^a,b,c   Sun, Y ^a,b,c   Dorbic, T ^b   Alijagic, S ^a,c   Makki, A ^a   Jurgovsky, K ^a,b   Schroff, M ^b   Henz, B M ^a   Wittig, B ^b   Schadendorf, D ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c DKFZ   (Germany)

Author keywords

Ballistic particle transfer; Cytolytic T lymphocyte; Gene transfer; Limited dilution transfer

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 7; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; TUMOR VACCINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; FEVER; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; MALE; MELANOMA; MELANOMA CELL; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

EID: 0031749740     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.317     Document Type: Article

References (40)

1. Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF and Schaid DJ (1989) Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63: 224-227
2. Alderson MR, Sassenfeld HM and Widmer RB (1990) Interleukin-7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 172: 577-587
3. Alderson MR, Tough TW, Ziegler SF and Grabstein KH (1991) Interleukin-7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 173: 923-930
4. Blumberg RS, Panadis T, Byington R, Henle W, Hirsch MS and Schooley RT (1987) Effects of human immunodeficiency virus on cellular immune response to Epstein-Barr virus in homosexual men: characterisation of cytotoxic response and lymphokine production. J Infect Dis 155: 877-890
5. Böhm M, Möller P, Kalbfleisch U, Worm M, Czarnetzki BM and Schadendorf D (1994) Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. Br J Cancer 70: 54-59
6. Boon T, Coulie P, Marchand M, Weynants P, Wölfel T and Brichard V (1994) Genes coding for tumour rejection antigens: perspectives for specific immunotherapy. In Important Advances in Oncology, DeVita VT, Hellman S and Rosenberg SA. (eds), pp. 53-69. Lippincott: Philadelphia
7. Celis E, Van Tsai A, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A and Serra HM (1994) Induction of anti-tumour cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105-2109
8. Colombo MP and Forni G (1994) Cytokine gene transfer in tumour inhibition and tumour therapy: where are we now? Immunol Today 15: 48-51
9. Coulie P, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R and Boon T (1992) Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 50: 289-297
10. Culver KW (1996) Measuring success in clinical gene therapy research. Mol Med Today 2: 234-236
11. Decker T and Lohmann-Matthes ML (1988) A quick and simple method for quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumour necrosis factor (TNF) activity. J Immunol Methods 15: 61-69
12. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Livitsky HI, Simons JW, Karasuyama H, Vogelstein B and Frost P (1990) Interleukin-2 production by tumour cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403
13. Ferrone S (1994) Melanoma, immune surveillance, and immunotherapy. J Clin Invest 93: 1351-1352
14. Filion MC, Bradley AJ, Devine DV, Decary F and Chartrand P (1995) Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur J Immunol 25: 3123-3127
15. Finke S, Grimm B, Möller P, Schadendorf D, Neubauer A, Huhn D and Schmidt-Wolf I (1997) Increase of cytotoxic sensitivity of primary melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. Cancer Gene Ther (in press)
16. Gansbacher B, Houghton AN, Livingston P, Minasian L, Rosenthal F, Gilboa E, Golde D, Oettgen H, Steffen T, Yang SY and Wong G (1992) A pilot study of immunisation with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther 3: 677-690
17. Herr W, Wölfel T Heike M, Meyer zum Büschenfelde KH and Knuth A (1994) Frequency analysis of tumour-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumour cells. Cancer Immunol Immunother 39: 93-99
18. Hickman CJ, Crim JA, Mostowski HS and Siegel JP (1990) Regulation of human cytotoxic T lymphocyte development by IL-7. J Immunol 145: 2415-2420
19. Ho VC and Sober AJ (1990) Therapy of cutaneous melanoma: an update. J Am Acad Dermatol 22: 159-176
20. Hock H, Dorsch M, Kunzendorf U, Zhihai Q, Diamantstein T and Blankenstein T (1993) Mechanisms of rejection induced by tumour cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumour necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90: 2774-2778
21. Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180: 1-7
22. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T and Rosenberg SA (1994) Identification of a human melanoma antigen recognised by tumour-infiltrating lymphocytes associated with in vivo tumour rejection. Proc Natl Acad Sci USA 91: 6458-9462
23. Kos FJ and Müllbacher A (1992) Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. Eur J Immunol 22: 3183-3185
24. Mackensen A, Carcelain G, Viel S, Raynal M-C, Michalaki H, Triebel F, Bosq J and Hercend T (1994) Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 93: 1391-1402
25. Miller AR, McBride WH, Dubinett SM, Dougherty GJ, Thacker JD, Shau H, Kohn DB, Moen RC, Walker MJ, Chui R, Schuck BL, Rosenblatt JA, Huang M, Dhanani S, Rhoades K and Economou J (1993) Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral-mediated gene transfer: comparison of immunological properties with interleukin-2. Blood 82: 3686-3694
26. Namen AE, Schmierer AE, March CJ, Overell RW, Park LS, Urdal DL and Mochizuki DY (1988) B cell precursor growth-promoting activity. J Exp Med 167: 988-1002
27. Naume B and Espevik T (1991) Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. J Immunol 147: 2208-2214
28. Oettgen HF and Old LJ (1991) The history of cancer immunotherapy. In Biologic Therapy of Cancer, Principles and Practice, de Vita VT, Helman S and Rosenberg SA. (eds), p. 87. Lippincott: Philadelphia
29. Old LJ (1981) Cancer immunology: the search for specificity - GHA Clowes Memorial Lecture. Cancer Res 41: 365-370
30. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13: 399-415
31. Robbins PF, El-Gamil M, Kawakami Y and Rosenberg SA (1994) Recognition of tyrosinase by tumour-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54: 3124-3126
32. Schadendorf D, Worm M, Algermissen B, Kohlmus CM and Czarnetzki BM (1994) Chemosensitivity testing of human malignant melanoma - a retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 73: 103-108
33. Schadendorf D, Makki A, Stahr C, Van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R and Henz BM (1995) Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 147: 1545-1552
34. Schadendorf D, Czarnetzki BM and Wittig B (1995) Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma. J Mol Med 73: 473-477
35. Schadendorf D, Fichtner I, Makki A, Alijagic S, Küpper M, Mrowietz U and Henz BM (1996) Metastatic potential of human melanoma cells in nude mice - characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer 73: 194-199
36. Schmidt-Wolf GH and Schmidt-Wolf IGH (1995) Cytokines and cytokine gene therapy. Eur J Immunol 25: 1137-1140
37. Schroff M, Schinagl M, Ertz S, Takeya M, Brendel S, Dorbic T, Möller P, Schadendorf D and Wittig B (1997) Ballisto-magnetic transfer of expression vectors into human cell nuclei, ex vivo, and its application in cancer gene therapy. (submitted)
38. Taswell C (1981) Limiting dilution assay for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126: 1614-1619
39. Tepper RI, Pattengale PK and Leder P (1989) Murine interleukin 4 displays potent anti-tumour activity in vivo. Cell 57: 503-512
40. Vieweg J and Gilboa E (1995) Considerations for the use of cytokine-secreting tumour cell preparations for cancer treatment. Cancer Treat Rev 13: 193-201